These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32663199)

  • 21. A neutralizing antibody that blocks delivery of the enzymatic cargo of
    Kroh HK; Chandrasekaran R; Zhang Z; Rosenthal K; Woods R; Jin X; Nyborg AC; Rainey GJ; Warrener P; Melnyk RA; Spiller BW; Lacy DB
    J Biol Chem; 2018 Jan; 293(3):941-952. PubMed ID: 29180448
    [No Abstract]   [Full Text] [Related]  

  • 22. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
    Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
    PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
    Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
    mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.
    Hussack G; Arbabi-Ghahroudi M; van Faassen H; Songer JG; Ng KK; MacKenzie R; Tanha J
    J Biol Chem; 2011 Mar; 286(11):8961-76. PubMed ID: 21216961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB.
    Lanis JM; Heinlen LD; James JA; Ballard JD
    PLoS Pathog; 2013; 9(8):e1003523. PubMed ID: 23935501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
    Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
    Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibodies specific for Clostridium difficile toxin B and their use in immunoassays.
    Müller F; Stiegler C; Hadding U
    J Clin Microbiol; 1992 Jun; 30(6):1544-50. PubMed ID: 1378062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
    Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
    Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immune response as predictor of recurrence in Clostridium difficile infection.
    Bauer MP; Nibbering PH; Poxton IR; Kuijper EJ; van Dissel JT
    Clin Microbiol Infect; 2014 Dec; 20(12):1323-8. PubMed ID: 25041274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrinsic Toxin-Derived Peptides Destabilize and Inactivate
    Larabee JL; Bland SJ; Hunt JJ; Ballard JD
    mBio; 2017 May; 8(3):. PubMed ID: 28512094
    [No Abstract]   [Full Text] [Related]  

  • 33. Functional defects in
    Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
    J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
    [No Abstract]   [Full Text] [Related]  

  • 34. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study.
    Islam J; Taylor AL; Rao K; Huffnagle G; Young VB; Rajkumar C; Cohen J; Papatheodorou P; Aronoff DM; Llewelyn MJ
    Anaerobe; 2014 Jun; 27():82-6. PubMed ID: 24708941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of Clostridium difficile toxin A using antibody combinations.
    Demarest SJ; Hariharan M; Elia M; Salbato J; Jin P; Bird C; Short JM; Kimmel BE; Dudley M; Woodnutt G; Hansen G
    MAbs; 2010; 2(2):190-8. PubMed ID: 20150758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection from Clostridium difficile infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice.
    Johnston PF; Gerding DN; Knight KL
    Infect Immun; 2014 Feb; 82(2):522-31. PubMed ID: 24478068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
    Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
    Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of the full-length Clostridium difficile toxin B.
    Chen P; Lam KH; Liu Z; Mindlin FA; Chen B; Gutierrez CB; Huang L; Zhang Y; Hamza T; Feng H; Matsui T; Bowen ME; Perry K; Jin R
    Nat Struct Mol Biol; 2019 Aug; 26(8):712-719. PubMed ID: 31308519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.